Peroxynitrite-induced relaxation in isolated canine cerebral arteries and mechanisms of action

Toxicology and Applied Pharmacology

Volumn 196, Issue 1, 2004, Pages 176-182

  Li, Jianfeng ^a   Li, Wenyan ^a   Altura, Bella T ^a,b   Altura, Burton M ^a,b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b SUNY Downstate Medical Center   (United States)

Author keywords

Canine cerebral artery; cGMP; Hyperpolarization; Oxidants; Peroxynitrite; Reactive oxygen species; Relaxation

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ARGININE; ATROPINE; CALCIUM ION; CALYCULIN A; CIMETIDINE; DIPHENHYDRAMINE; GLIBENCLAMIDE; HALOPERIDOL; INDOMETACIN; METHYLENE BLUE; MYOSIN LIGHT CHAIN PHOSPHATASE; N(G) NITROARGININE METHYL ESTER; NALOXONE; PEROXYNITRITE; POTASSIUM CHANNEL; POTASSIUM CHLORIDE; PROSTAGLANDIN F2; TETRYLAMMONIUM CHLORIDE;

ANIMAL TISSUE; ARTICLE; BASILAR ARTERY; BRAIN ARTERY; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; ENZYME ACTIVITY; HYPERPOLARIZATION; MEMBRANE POTENTIAL; NONHUMAN; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; CEREBRAL ARTERIES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PEROXYNITROUS ACID; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 1642367751     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.taap.2003.12.007     Document Type: Article

References (41)

1. Ademoglu F., Basgut B., Abacioglu N., Cakici I. The mechanisms of peroxynitrite-induced relaxations in isolated rat anococcygeus muscle. Pharmacology. 66:2002;1-4.
2. Altura B.M., Altura B.T. Differential effects of substrate depletion on drug-induced contractions of rabbit aorta. Am. J. Physiol. 219:1970;1698-1705.
3. Altura B.M., Altura B.T. Peripheral vascular actions of glucocorticoids and their relationship to protection in circulatory shock. J. Pharmacol. Exp. Ther. 190:1974;300-315.
4. Altura B.T., Altura B.M. Withdrawal of magnesium causes vasospasm while elevated magnesium produces relaxation of tone in cerebral arteries. Neurosci. Lett. 20:1980;323-327.
5. Archer S.L., Huang J.M., Hampl V., Nelson D.P., Shultz P.J., Weir E.K. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc. Natl. Acad. Sci. U.S.A. 91:1994;7583-7587.
6. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75:1995;725-748.
7. Beckman J.S. The double-edged role of nitric oxide in brain function and superoxide-mediated injury. J. Dev. Physiol. 15:1991;53-59.
8. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. U.S.A. 87:1990;1620-1624.
9. Beckman J.S., Chen J., Crow J.P., Ye Y.Z. Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration. Prog. Brain Res. 103:1994;371-380.
10. Bohr D.F. Vascular smooth muscle updated. Circ. Res. 32:1973;665-672.
11. Brayden J.E., Quayle J.M., Standen N.B., Nelson M.T. Role of potassium channels in the vascular response to endogenous and pharmacological vasodilators. Blood Vessels. 28:1991;147-153.
12. Brzezinska A.K., Gebremedhin D., Chilian W.M., Kalyanaraman B., Elliott S.J. Peroxynitrite reversibly inhibits Ca(2+)-activated K(+) channels in rat cerebral artery smooth muscle cells. Am. J. Physiol.: Heart Circ. Physiol. 278:2000;H1883-H1890.
13. Cohen P. The structure and regulation of protein phosphatases. Adv. Second Messenger Phosphoprotein Res. 24:1990;230-235.
14. Dowell F.J., Martin W. The effects of peroxynitrite on rat aorta: interaction with glucose and related substances. Eur. J. Pharmacol. 338:1997;43-53.
15. Dowell F.J., Martin W. Interaction between peroxynitrite and L-cysteine: effects on rat aorta. Eur. J. Pharmacol. 344:1998;183-190.
16. Elliott S.J., Lacey D.J., Chilian W.M., Brzezinska A.K. Peroxynitrite is a contractile agonist of cerebral artery smooth muscle cells. Am. J. Physiol. 275(5 Pt. 2):1998;H1585-H1591.
17. Endres M., Scott G., Namura S., Salzman A.L., Huang P.L., Moskowitz M.A., Szabo C. Role of peroxynitrite and neuronal nitric oxide synthase in the activation of poly(ADP-ribose) synthetase in a murine model of cerebral ischemia-reperfusion. Neurosci. Lett. 248:1998;41-44.
18. Godfraind T., Kaba A. Blockade or reversal of the contraction induced by calcium and adrenaline in depolarized arterial smooth muscle. Br. J. Pharmacol. 36:1969;549-560.
19. Graves J.E., Lewis S.J., Kooy N.W. Peroxynitrite-mediated vasorelaxation: evidence against the formation of circulating S-nitrosothiols. Am. J. Physiol. 274(Pt. 2):1998;H1001-H11008.
20. Horowitz A., Menice C.B., Laporte R., Morgan K.G. Mechanisms of smooth muscle contraction. Physiol. Rev. 76:1996;967-1003.
21. 2. Am. J. Physiol. 277(3 Pt. 2):1999;H978-H985.
22. Ischiropoulos H., Zhu L., Chen J., Tsai M., Martin J.C., Smith C.D., Beckman J.S. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 298:1992;431-437.
23. Li W., Altura B.T., Altura B.M. Differential effects of methanol on rat aortic smooth muscle. Alcoholism. 16:1998;221-229.
24. Lincoln T.M. Cyclic GMP and mechanisms of vasodilation. Pharmacol. Ther. 41:1989;479-502.
25. Lincoln T.M., Dey N., Sellak H. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J. Appl. Physiol. 91:2001;1421-1430.
26. Liu S., Beckman J.S., Ku D. Peroxynitrite, a product of superoxide and nitric oxide, produces coronary vasorelaxation in dogs. J. Pharmacol. Exp. Ther. 268:1994;1114-1121.
27. Medina P., Segarra G., Vila J.M., Domenech C., Martinez-Leon J.B., Lluch S. Effects of sildenafil on human penile blood vessels. Urology. 56:2000;539-543.
28. Mochida H., Inoue H., Takagi M., Noto T., Yano K., Kikkawa K. Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta. Eur. J. Pharmacol. 440:2002;45-52.
29. Moro M.A., Darley-Usmar V.M., Goodwin D.A., Read N.G., Zamora-Pino R., Feelisch M., Radomski M.W., Moncada S. Paradoxical fate and biological action of peroxynitrite on human platelets. Proc. Natl. Acad. Sci. U.S.A. 91:1994;6702-6706.
30. Onoue H., Katusic Z.S. Role of potassium channels in relaxations of canine middle cerebral arteries induced by nitric oxide donors. Stroke. 28:1997;1264-1271.
31. 2. Life Sci. 66:2000;PL291-PL296.
32. Virag L., Marmer D.L., Szabo C. Crucial role of apopain in the peroxynitrite-induced apoptotic DNA fragmentation. Free Radical Biol. Med. 25:1998;1075-1082.
33. Wei E.P., Kontos H.A., Beckman J.S. Mechanisms of cerebral vasodilation by superoxide, hydrogen peroxide, and peroxynitrite. Am. J. Physiol. 271(Pt. 2):1996;H1262-H1266.
34. Wu M., Pritchard K.A. Jr., Kaminski P.M., Fayngersh R.P., Hintze T.H., Wolin M.S. Involvement of nitric oxide and nitrosothiols in relaxation of pulmonary arteries to peroxynitrite. Am. J. Physiol. 266(Pt. 2):1994;H2108-H2113.
35. Yang Z.W., Zheng T., Zhang A., Altura B.T., Altura B.M. Mechanisms of hydrogen peroxide-induced contraction of rat aorta. Eur. J. Pharmacol. 344:1998;169-181.
36. i in canine cerebral arterial smooth muscle: participation of cellular signaling pathways. Naunyn-Schmiedeberg's Arch. Pharmacol. 360:1999;646-653.
37. +. Br. J. Pharmacol. 105:1992;305-310.
38. Zhang A., Cheng T.P., Altura B.M. Magnesium regulates intracellular free ionized calcium concentration and cell geometry in vascular smooth muscle cells. Biochim. Biophys. Acta. 1134:1992;25-29.
39. Zhang A., Altura B.T., Altura B.M. Ethanol-induced contraction of cerebral arteries in diverse mammals and its mechanism of action. Eur. J. Pharmacol. 248:1993;229-236.
40. i in cultured canine cerebral vascular smooth muscle cells. Neurosci. Lett. 245:1998;17-20.
41. Zingarelli B., Hasko G., Salzman A.L., Szabo C. Effects of a novel guanylyl cyclase inhibitor on the vascular actions of nitric oxide and peroxynitrite in immunostimulated smooth muscle cells and in endotoxic shock. Crit. Care Med. 27:1999;1701-1707.